Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|September 28, 2026

The BioPharm Brief: Weekly Insulin, Excipient Data, and the Fate of a Lung Cancer ADC

Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, regulatory progress, and drug development. Today’s update covers a new once-weekly insulin option for type 2 diabetes, efforts to standardize excipient information sharing, and a regulatory setback for an antibody-drug conjugate in small cell lung cancer.

First, FDA approved Eli Lilly and Company’s Onswik as a once-weekly basal insulin for adults with type 2 diabetes. The approval is supported by a phase 3 program that enrolled more than 3400 participants across 4 registration studies. Onswik achieved noninferior A1C reductions compared with daily insulin glargine or insulin degludec. By reducing basal insulin injections from roughly 365 to 52 per year, the therapy could change how some patients manage long-term insulin treatment. It is not indicated for type 1 diabetes because of an increased risk of severe hypoglycemia.

Shifting from clinical development to pharmaceutical manufacturing, another initiative focuses on improving how excipient information moves between suppliers and drug manufacturers. The International Pharmaceutical Excipients Council’s Excipient Information Package, or EIP, provides a standardized framework for sharing quality, regulatory, supply-chain, and security information. The approach is intended to reduce the need for companies to complete multiple customer-specific questionnaires while helping suppliers provide consistent information more efficiently.

Meanwhile, the oncology pipeline saw a regulatory setback. Daiichi Sankyo and Merck voluntarily withdrew their FDA application for ifinatamab deruxtecan, or I-DXd, in previously treated extensive-stage small cell lung cancer after discussions with FDA indicated that phase 2 data did not support accelerated approval. The companies continue enrolling patients in a phase 3 trial, which could provide data for a future filing.

Collectively, these stories show how biopharma progress depends on advancing patient-friendly therapies while strengthening the technical and regulatory processes supporting development.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • Weekly insulin could reduce treatment burden for adults with type 2 diabetes.
  • Standardized excipient data sharing may improve pharmaceutical supply-chain efficiency.
  • Daiichi Sankyo and Merck continue evaluating ifinatamab deruxtecan after withdrawing its SCLC filing.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.